GlassScriptPhysician profile
Shannon H Kasperbauer
NPI 1962558635
$94,375.13
in general payments reported to CMS, 2019-2025
9 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,993 · 2020: $14K · 2021: $9,564 · 2022: $1,704 · 2023: $2,000 · 2024: $29K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $53K · Travel and Lodging: $3,434 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800 · Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,124.39 |
| Travel and Lodging | $3,433.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
| Food and Beverage | $969.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $86,251.59 | 2019-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $3,771.79 | 2021-2022 | |
| Zambon USA LTD. | $2,381.89 | 2024 | |
| Mannkind Corporation | $1,800.00 | 2025 | |
| Electromed, INC. | $100.82 | 2023-2025 | Smartvest |
| Grifols USA, LLC | $27.60 | 2023 | Prolastin-C Liquid |
| Shionogi INC | $15.39 | 2022 | |
| Allergan, INC. | $13.51 | 2020 | |
| Abbvie INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Kasperbauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.